SEC Form 4 · accession 0001225208-19-004220
PFIZER INC · PFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John D Young
Officer — Group President
Period of report
Feb 27, 2019
Accepted (ET)
Mar 1, 2019 · 7:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000078003
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 27, 2019 | M | 154,374 | $32.23 | A | 441,923 | D | |
| Common StockF2 | Feb 27, 2019 | A | 96,183 | $0.00 | A | 538,106 | D | |
| Common StockF3 | Feb 27, 2019 | F | 28,910 | $42.93 | D | 509,196 | D | |
| Common StockF4 | Feb 27, 2019 | F | 47,101 | $42.93 | D | 462,095 | D | |
| Common StockF5,F6 | Feb 27, 2019 | F | 95,338 | $42.31 | D | 366,757 | D | |
| Common Stock | holding | — | — | — | 1,927 | I | By Rule 16b-3 Plan | |
| Common Stock | holding | — | — | — | 1,471 | I | By Trustee under the Pfizer Share Ownership Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation Rights | $32.23 | Feb 27, 2019 | M | 154,374 | D | Feb 27, 2019 | Feb 27, 2019 | Common Stock | 154,374 | 0 | D |
| Stock Appreciation RightsF7 | $43.35 | Feb 28, 2019 | A | 120,335 | A | Feb 28, 2024 | Feb 28, 2024 | Common Stock | 120,335 | 120,335 | D |
| Stock Appreciation RightsF8 | $43.35 | Feb 28, 2019 | A | 101,409 | A | Feb 28, 2026 | Feb 28, 2026 | Common Stock | 101,409 | 101,409 | D |
Explanation of responses
- F1The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
- F2The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon).
- F3The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
- F4The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon).
- F5The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
- F6Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
- F7The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
- F8The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.